ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY. (12th June 2019) - Davies, A.J.; Tansley Hancock, O.; Cummin, T.; Caddy, J.; Stanton, L.; Burton, C.; Barrans, S.; Coleman, A.; Osborne, W.; McKay, P.; Griffiths, G.; Johnson, P.